Highlights
- Celldex reported its Phase 2 atopic dermatitis study missed its primary itch endpoint and is discontinuing development in that indication.
- Net loss was $75.6 million for the three months ended September 30, 2026, compared with $67.0 million a year earlier.
- Cash, cash equivalents and marketable securities were $650.3 million at September 30, 2026; nine-month net loss was $227.7 million.
- Celldex anticipates submitting a Biologics License Application for barzolvolimab in chronic spontaneous urticaria to the FDA in 2027.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares were trading at USD 27.58 on November 20, 2026, down 1.36%, with a relative Volume at time of 3.02. The clinical-stage biopharmaceutical company filed its report for the quarter ended September 30, 2026 on November 5, and announced after the close on November 19 that its Phase 2 atopic dermatitis study of barzolvolimab missed its primary itch endpoint.
Celldex is a Delaware corporation with principal executive offices in Hampton, New Jersey. It develops antibody-based therapeutics for inflammatory and other difficult-to-treat diseases, with barzolvolimab, an antibody directed at the KIT receptor on mast cells, as its lead program. The company is managed as a single operating and reportable segment, and its fiscal year ends on December 31. It had total revenues of $0.04 million for the nine months ended September 30, 2026 and reports recurring losses.
Atopic Dermatitis Study Result
Celldex announced that its Phase 2 study of barzolvolimab in moderate-to-severe atopic dermatitis missed its primary itch endpoint and key secondary endpoints, EASI and IGA. The company said it is discontinuing development of barzolvolimab in that indication. The company reported that the 300 mg dose showed -29.2% versus -19.5% for placebo (p=0.187). Celldex also said a Biologics License Application for chronic spontaneous urticaria is planned for 2027, Phase 3 studies in cold urticaria and dermographism are enrolling, and new indications will be announced by year end.
Third Quarter 2026 Results
For the three months ended September 30, 2026, Celldex reported no revenues, compared with no revenues a year earlier. Research and Development expense was $67.4 million, compared with $62.9 million, and general and administrative expense was $14.8 million, compared with $10.7 million. Operating loss was $82.3 million, compared with $73.6 million. Net loss was $75.6 million, or $(0.96) per basic and diluted share, compared with $67.0 million, or $(1.01) per share.
For the nine months ended September 30, 2026, total revenues were $0.04 million, compared with $1.4 million. Research and development expense was $208.0 million, compared with $169.7 million, and general and administrative expense was $39.4 million, compared with $31.9 million. Operating loss was $247.3 million, compared with $200.2 million. Net loss was $227.7 million, or $(3.06) per basic and diluted share, compared with $177.4 million, or $(2.67) per share.
Balance Sheet, Cash Flow and Capital
At September 30, 2026, cash and cash equivalents were $27.0 million and marketable securities were $623.4 million. Total Assets were $721.5 million, compared with $583.0 million at December 31, 2025. Total liabilities were $72.1 million, compared with $55.8 million.
Net cash used in Operating Activities was $188.0 million for the nine months, compared with $147.0 million a year earlier. In April 2026, the company issued 11,896,750 shares of common stock in an underwritten public offering, with net proceeds of $323.8 million after Underwriting fees and offering expenses. The at-the-market agreement expired on November 3, 2026, and no shares were sold under it before expiration.
The filing states that the company has had recurring losses and incurred a loss of $227.7 million for the nine months ended September 30, 2026. The company said it believes its cash, cash equivalents and marketable securities will be sufficient to fund planned operations for at least the next twelve months from the date the financial statements were issued, and that it may take further steps to raise additional capital.
Barzolvolimab Program Update
In September 2026, Celldex announced topline results from two Phase 3 studies of barzolvolimab in chronic spontaneous urticaria, which the company said met the primary and all key secondary endpoints at Week 12 across both studies and both dose groups. Treatment continues in both trials to 52 weeks, and a Biologics License Application submission to the FDA is anticipated in 2027.






Please wait processing your request...